EB Pharma Developments
The abbreviated and micro formats do not require turnover, and these accounts state none. Without turnover there is no EBIT margin either.
Balance sheet
balance sheet total €16,951 on 31-12-2025in euro
in euro
Position in the sector
31.3%
Higher than 39% of the 734 companies filing abbreviated accounts in other professional activities (NACE 74) in 2025.
1.45
Higher than 43% of the 710 companies filing abbreviated accounts in other professional activities (NACE 74) in 2025.
-7.9%
Higher than 17% of the 715 companies filing abbreviated accounts in other professional activities (NACE 74) in 2025.
Net result: middle half · Equity: bottom quarter · Balance sheet total: bottom quarter · Working capital: middle half
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 202211 months |
|---|---|---|---|---|---|
| -883 | 4,919 | -7,782 | - | ||
| 5,298 | 16,645 | 13,078 | 17,722 | ||
| 31.3% | 87.3% | 100.0% | 80.4% | ||
| 1.45 | 7.88 | - | 5.11 | ||
| 2.20 | 0.15 | 0.00 | 0.24 | ||
| -25.4% | 21.4% | -35.5% | 91.5% | ||
| -7.9% | 18.7% | -35.5% | 73.6% |
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 202211 months |
|---|---|---|---|---|---|
| Balance sheet: assets | |||||
20/58 |
16,951 | 19,064 | 13,078 | 22,037 | |
29/58 |
16,951 | 19,064 | 13,078 | 22,037 | |
40/41 |
8,215 | 9,445 | 8,378 | 9,555 | |
40 |
0 | 3,880 | 823 | - | |
41 |
8,215 | 5,565 | 7,555 | 9,555 | |
54/58 |
8,736 | 9,619 | 4,700 | 12,482 | |
| Balance sheet: equity and liabilities | |||||
10/49 |
16,951 | 19,064 | 13,078 | 22,037 | |
10/15 |
5,298 | 16,645 | 13,078 | 17,722 | |
10/11 |
1,500 | 1,500 | 1,500 | 1,500 | |
13 |
3,798 | 15,145 | 11,578 | 16,222 | |
133 |
3,798 | 15,145 | 11,578 | 16,222 | |
14 |
0 | - | - | - | |
17/49 |
11,654 | 2,420 | 0 | 4,316 | |
42/48 |
11,654 | 2,420 | 0 | 4,316 | |
44 |
636 | 1,920 | - | - | |
440/4 |
636 | 1,920 | - | - | |
45 |
- | - | 0 | 4,316 | |
450/3 |
- | - | 0 | 4,316 | |
47/48 |
11,018 | 500 | - | - | |
| Income statement | |||||
9900 |
-1,127 | 3,749 | -4,297 | 20,964 | |
640/8 |
462 | 449 | 446 | 348 | |
9901 |
-1,589 | 3,300 | -4,744 | 20,616 | |
75/76B |
364 | 1,675 | 196 | - | |
75 |
364 | 1,675 | 196 | - | |
65/66B |
123 | 1,408 | 97 | 79 | |
65 |
123 | 1,408 | 97 | 79 | |
9903 |
-1,347 | 3,567 | -4,644 | 20,537 | |
67/77 |
- | - | 0 | 4,316 | |
9904 |
-1,347 | 3,567 | -4,644 | 16,222 | |
9905 |
-1,347 | 3,567 | -4,644 | 16,222 | |
| Appropriation of the result | |||||
9906 |
-1,347 | 3,567 | -4,644 | 16,222 | |
791/2 |
11,347 | 0 | 4,644 | - | |
691/2 |
0 | 3,567 | 0 | 16,222 | |
6921 |
0 | 3,567 | 0 | 16,222 | |
694/7 |
10,000 | - | - | - | |
694 |
10,000 | - | - | - | |
| Document | |||||
The full notes are in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 25-03-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankInsights on EB Pharma Developments
The operating result for 2025 is a loss of €1,589, after a profit of €3,300 in 2024.
Debt's share of the balance-sheet total rises from 12.7% to 68.7%. Equity is lower and debt is higher.